scholarly journals Effects of family history of diabetes on pancreatic β-cell function and diabetic ketoacidosis in newly diagnosed patients with type 2 diabetes: a cross-sectional study in China

BMJ Open ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. e041072
Author(s):  
Xiaofen Xiong ◽  
Ling Wei ◽  
Ying Xiao ◽  
Yachun Han ◽  
Jinfei Yang ◽  
...  
Keyword(s):  
Cell Function ◽  
Cross Sectional Study ◽  
Β Cell ◽  
Cross Sectional ◽  
Parental History ◽  
High Prevalence ◽  
Β Cell Function ◽  
History Of ◽  
Parental History Of Diabetes

ObjectiveTo investigate the association between a parental and/or sibling history of diabetes and clinical characteristics.DesignA cross-sectional study.SettingThe data were collected from the endocrinology department of The Second Xiangya Hospital of Central South University from June 2017 to October 2019.ParticipantsA total of 894 newly diagnosed patients with type 2 diabetes were recruited. Data on clinical characteristics were collected from patient medical records. Pancreatic β-cell function and insulin resistance were calculated with the homeostatic model assessment. SPSS V.25.0 was used to perform the analysis.ResultsThe percentages of patients with parental and sibling histories of diabetes were 14.8% and 9.8%, respectively. The prevalence of diabetic ketoacidosis (DKA) was 3.9%. Compared with those with no parental history of diabetes, patients with a parental history of diabetes were characterised by early-onset disease (41.70±10.88 vs 51.17±14.09 years), poor glycaemic control of fasting blood glucose (10.84±5.21 vs 8.91±4.38 mmol/L) and a high prevalence of DKA (7.6% vs 3.3%). The patients with a sibling history of diabetes had later disease onset (56.05±9.86 vs 49.09±14.29 years) and lower BMI (24.49±3.48 vs 25.69±3.86 kg/m2) than those with no sibling history of diabetes. Univariate regression suggested that both parental history (p=0.037) and sibling history (p=0.011) of diabetes were associated with β-cell function; however, multiple regression analysis showed that only a sibling history of diabetes was associated with β-cell function (p=0.038). Univariate regression revealed a positive correlation between parental history of diabetes (p=0.023, OR=2.416, 95% CI 1.132 to 5.156) and DKA. Unfortunately, this correlation was not statistically significant for either patients with a parental history (p=0.234, OR=1.646, 95% CI 0.724 to 3.743) or those with a sibling history (p=0.104, OR=2.319, 95% CI 0.841 to 6.389) after adjustments for confounders.ConclusionA sibling history of diabetes was associated with poor β-cell function, and a parental history of diabetes was associated with poor glycaemic control and a high prevalence of DKA.

scholarly journals Family history of diabetes in both parents is strongly associated with impaired residual β‐cell function in Japanese type 2 diabetes patients

2019 ◽  
Vol 11 (3) ◽  
pp. 564-572
Author(s):  
Minoru Iwata ◽  
Yutaka Kamura ◽  
Hisae Honoki ◽  
Kaori Kobayashi ◽  
Manabu Ishiki ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Family History ◽  
Cell Function ◽  
Β Cell ◽  
Family History Of Diabetes ◽  
Β Cell Function ◽  
History Of ◽  
Diabetes Patients

scholarly journals Ten-year follow-up of sitagliptin treatment in patients with type 2 diabetes mellitus

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Sachiko Hattori
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Cell Function ◽  
Urinary Albumin ◽  
Control Group ◽  
Β Cell ◽  
Glucose Lowering ◽  
Β Cell Function ◽  
History Of

Abstract Background Early and effective intervention with a dipeptidyl peptidase 4 inhibitor (DPP4i) before the development of advanced atherosclerosis in type 2 diabetes mellitus (T2DM) patients without a history of cardiovascular disease (CVD) is reported to increase the chance of significant reductions in not only microvascular disease, but also CVD. Method This study aimed to investigate whether sitagliptin is effective and tolerated for glycemic control and whether renoprotective effects and β-cell function are preserved for as long as ten years in Japanese patients with T2DM without a history of CVD. Results The situation is equivalent to improving glycemic control as assessed by hemoglobin A1c both in a sitagliptin group [sitagliptin 50 mg as either monotherapy or combination therapy with other oral glucose-lowering drugs (n = 17)] or a control group [placebo as either monotherapy or combination therapy with other glucose-lowering drugs (n = 9)], while anti-inflammatory effects as assessed by high-sensitivity C-reactive peptide in the sitagliptin group were superior to those in the control group. In the sitagliptin group, mean urinary albumin excretion (measured as urinary albumin-to-creatinine ratio) was markedly decreased, but no changes in estimated glomerular filtration rate were seen throughout the study. Beta-cell function as evaluated by homeostatic model assessment of β-cell function values was reduced at baseline in both groups, improved significantly in the sitagliptin group, and continued unchanged in the control group during the study. Conclusion These observations suggest that early intervention with sitagliptin in patients with T2DM may have long-lasting renoprotective and islet-protective effects. Trial registration: UMIN Clinical Registry (UMIN000038459). Registered 01 November (retrospectively registered): https://upload.umin.ac.jp/UMIN000038459

scholarly journals Association of Insulin Resistance and β-cell Function With Bone Turnover Biomarkers in Dysglycemia Patients

2021 ◽  
Vol 12 ◽  
Author(s):  
Hui Guo ◽  
Chiyu Wang ◽  
Boren Jiang ◽  
Shaohong Ge ◽  
Jian Cai ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Bone Turnover ◽  
Type I Collagen ◽  
Cell Function ◽  
Cross Sectional Study ◽  
Type I ◽  
Model Assessment ◽  
Β Cell ◽  
Cross Sectional ◽  
Β Cell Function

BackgroundThe interrelation between glucose and bone metabolism is complex and has not been fully revealed. This study aimed to investigate the association between insulin resistance, β-cell function and bone turnover biomarker levels among participants with abnormal glycometabolism.MethodsA total of 5277 subjects were involved through a cross-sectional study (METAL study, http://www.chictr.org.cn, ChiCTR1800017573) in Shanghai, China. Homeostasis model assessment of insulin resistance (HOMA-IR) and β-cell dysfunction (HOMA-%β) were applied to elucidate the nexus between β-C-terminal telopeptide (β-CTX), intact N-terminal propeptide of type I collagen (P1NP) and osteocalcin (OC). β-CTX, OC and P1NP were detected by chemiluminescence.ResultsHOMA-IR was negatively associated with β-CTX, P1NP and OC (regression coefficient (β) -0.044 (-0.053, -0.035), Q4vsQ1; β -7.340 (-9.130, -5.550), Q4vsQ1 and β -2.885 (-3.357, -2.412), Q4vsQ1, respectively, all P for trend <0.001). HOMA-%β was positively associated with β-CTX, P1NP and OC (β 0.022 (0.014, 0.031), Q4vsQ1; β 6.951 (5.300, 8.602), Q4vsQ1 and β 1.361 (0.921, 1.800), Q4vsQ1, respectively, all P for trend <0.001).ConclusionsOur results support that lower bone turnover biomarker (β-CTX, P1NP and OC) levels were associated with a combination of higher prevalence of insulin resistance and worse β-cell function among dysglycemia patients. It is feasible to detect bone turnover in diabetes or hyperglycemia patients to predict the risk of osteoporosis and fracture, relieve patients’ pain and reduce the expenses of long-term cure.

The impact of family history of type 2 diabetes on pancreatic β-cell function

2009 ◽  
Vol 86 (1) ◽  
pp. 61-66 ◽  
Author(s):  
Zhi-hong Wang ◽  
Su-Hua Zhang ◽  
Li-lin Gong ◽  
Wei Ren ◽  
Rong Li ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Family History ◽  
Cell Function ◽  
Pancreatic Β Cell ◽  
Β Cell ◽  
Β Cell Function ◽  
History Of ◽  
The Impact
Sign in / Sign up

Export Citation Format

Share Document